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Abstract Chromogranin A (CHGA) plays a fundamental
role in the biogenesis of catecholamine secretory granules.
Changes in storage and release of CHGA in clinical and
experimental hypertension prompted us to study whether
genetic variation at the CHGA locus might contribute to
alterations in autonomic function, and hence hypertension
and itstarget organ consequencessuch ashypertensive renal
disease (nephrosclerosis). Systematic polymorphism dis-
covery across the human CHGA locus revealed both com-
mon and unusual variants in both the open reading frame
and such regulatory regions as the proximal promoter and
30-UTR. In chromafﬁn cell-transfected CHGA 30-UTR and
promoter/luciferase reporter plasmids, the functional con-
sequences ofthe regulatory/non-coding allelicvariantswere
documented.Variantsinboththeproximalpromoterandthe
30-UTR displayed statistical associations with hypertension.
Genetic variationinthe proximalCHGA promoter predicted
glomerular ﬁltration rate in healthy twins. However, for
hypertensive renaldamage, bothend-stage renaldisease and
rate of progression of earlier disease were best predicted by
variants in the 30-UTR. Finally, mechanistic studies were
undertaken initiated by the clue that CHGA promoter vari-
ation predicted circulating endothelin-1. In cultured endo-
thelial cells, CHGA triggered co-release of not only the
vasoconstrictor and pro-ﬁbrotic endothelin-1, but also the
pro-coagulant von Willebrand Factor and the pro-angio-
genic angiopoietin-2. These ﬁndings, coupled with stimu-
lation of endothelin-1 release from glomerular capillary
endothelial cells by CHGA, suggest a plausible mechanism
whereby genetic variation at the CHGA locus eventuates in
alterations in human renal function. These results document
the consequences of genetic variation at the CHGA locus for
cardiorenal disease and suggest mechanisms whereby such
variation achieves functional effects.
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Introduction
Chromogranin A (CHGA: human, Chga: rodent) is the
major protein co-stored and co-released with catechola-
mines from secretory vesicles in adrenal medulla and
postganglionic sympathetic axons (Takiyyuddin et al.
1990b). CHGA is required for formation of catecholamine
secretory vesicles in chromafﬁn cells (Mahapatra et al.
2005) and its expression may be sufﬁcient even to induce a
regulated secretory system in non-secretory cells (Kim et al.
2001). CHGA is also a pro-hormone that gives rise to bio-
logically active peptides such as the dysglycemic peptide
pancreastatin (Cadman et al. 2002; Tatemoto et al. 1986),
the antimicrobial peptide chromacin (Strub et al. 1996), the
vasodilator vasostatin, and catestatin that acts to inhibit
catecholamine release (Mahata et al. 1999, 1997). Proteo-
lytic enzymes speciﬁcally catalyzing CHGA cleavage to
active peptides have been identiﬁed including the pro-hor-
mone convertases (Eskeland et al. 1996), plasmin (Jiang
et al. 2001; Parmer et al. 2000; Biswas et al. 2008), and
cathepsin L (Biswas et al. 2009).
Over the past *20 years, phenotypic links between
CHGA and hereditary (essential, idiopathic, and genetic)
human (Hsiao et al. 1991; O’Connor 1985; Takiyyuddin
et al. 1990a) and rodent (O’Connor et al. 1999; Fries et al.
2004) hypertension have been repeatedly observed. Plasma
CHGA concentration correlates with catecholamine release
rates (Dimsdale et al. 1992), and increases in blood pressure
caused by the action of catecholamines may be coupled to
the formation of dense-core secretory granules, whose bio-
genesis is regulated in vivo by CHGA (Mahapatra et al.
2005).IncreasedserumCHGAhasbeendetectednotonlyin
patients with essential hypertension (O’Connor 1985) but
also hypertensive consequences such as cardiac or renal
(Hsiao et al. 1990) failure. Intriguingly, targeted ablation of
the Chga locus in the mouse also results in elevated BP
(Mahapatra et al. 2005) and global autonomic dysfunction,
both sympathetic and parasympathetic (Gayen et al. 2009);
recently, using both knockout and replacement strategies,
we established that Chga gene copy number exhibits a
biphasic (or ‘‘U-shaped’’) effect on both BP and catechol-
amine release (Vaingankar et al. 2010a, b); we observed
parallel ﬁndings on CHGA secretion and autonomic stress
responses in humans (Vaingankar et al. 2010a, b), suggest-
ing that an optimal amount of CHGA may be required to
establishappropriatecatecholaminestorageandrelease,and
hence BP homeostasis.
We systematically identiﬁed genetic variation across the
human CHGA locus by resequencing the gene in several
human populations (Wen et al. 2004). We then explored
whether common genetic variation at the CHGA locus is
associated with hypertension or hypertensive complications
such as nephrosclerosis beginning with large population-
based samples. We then established an inﬂuence on an
earlier pathogenic phenotype (environmental stress-evoked
change in BP), and ﬁnally documented the effects on gene
expression in transfected reporter systems in chromafﬁn
cells.
Chromogranin A Genetic Variants and Hypertension
A common haplotype of the CHGA proximal promoter
region, CGATA (at T-1014C, T-988G, G-462A, C-415T,
and A-89C), blunted the BP response to cold stress, and the
response exhibited molecular heterosis (most extreme phe-
notype in heterozygotes) between the two most common
promoter haplotypes (CGATA/TTGTC) (Chen et al.
2008a). Homozygosity for the minor alleles at T-1014C
(C/C), T-988G (G/G), and G-462A (A/A) predicted lower
stress BP increments with peak prediction for G-462A
(rs9658634) heterozygotes (*6–7 mmHg). G-462A also
predicted resting BP in the population, accounting for
*3/2 mmHg SBP/DBP, once again with the appearance of
molecular heterosis (i.e., highest BP in G/A heterozygotes).
In transfected CHGA promoter/luciferase reporters,
CGATA had diminished expression compared to TTGTC,
under both basal conditions and after secretory activation by
pre-ganglionic stimuli (nicotinic cholinergic, VIP). Variant
G-462A altered a COUP-TF transcriptional control motif
and the two alleles in transfected promoters differed in basal
activity (G[A), as well as the response to COUP-II-TF
(A[G) and retinoic acid (G[A). Findings of molecular
heterosis were also demonstrated for the transfected CHGA
promoter in cella, wherein the diploid combination of the
two alleles at G-462A (G/A heterozygosity) gave rise to
greater luciferase expression than either allele in isolation
(Chen et al. 2008a).
A common (*27% allele frequency) genetic variant in
the CHGA 30-UTR (C ? 87T; rs7610) was strongly asso-
ciated with human essential hypertension, accounting for up
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123to *12/9 mmHgof BP inmen,or *1.9/1.2% ofpopulation
SBP/DBP variance, especially in males (Chen et al. 2008b).
The 30-UTR variant also predicts environmental stress-
induced increments in blood pressure: the same allele
(?87T) that diminished basal BP in the population also
decreased the SBP response to stress by *12 mmHg
(P = 0.017), and the response was smaller in women (by
*6 mmHg, P = 0.009), suggesting a mechanism for early
effects of the gene on a pathogenic series of events even-
tuating in sustained blood pressure elevation. The 30-UTR
variant is in a region of sequence conservation across
species, and acts to change CHGA gene expression in chro-
mafﬁncells.Inachromafﬁncell-transfectedCHGA30-UTR/
luciferase reporter plasmid, the ?87T allele associated with
lower BP also decreased reporter expression by *30%
(P = 0.009). In cultured chromafﬁn cells, reducing endog-
enous Chga expression by siRNA caused *2/3 depletion of
catecholamine storage vesicles (P\0.0001). At multiple
levels (CHGA expression, heritable circulatory response to
environmentalstress,andﬁnallybasalBPinthepopulation),
sex seemed to play an important role in mediating the effect
of genetic variation on phenotype (Chen et al. 2008b).
Chromogranin A Genetic Variants: Renal Function
and Hypertensive Nephrosclerosis
In African-Americans with a clinical diagnosis of hyper-
tensive renal disease (or nephrosclerosis) (Salem et al.
2008), genetic variation at CHGA predicts risk for devel-
oping the trait, and the peak effect lies in haplotypes
spanning the 30-end of the gene.
In a large twin pair sample with normal renal function,
glomerular ﬁltration rate (GFR) was highly heritable (at
h
2 = 78 ± 3%, P\10
-25), and CHGA common promoter
haplotypes (G-1106A, rs9658628; A-1018T, rs9658629;
T-1014C, rs9658630; T-988G, rs9658631; G-462A,
rs9658634; T-415C, rs9658635; C-89A, rs7159323;
C-57T, rs9658638) predicted GFR: haplotype-2 (GATT
GTCC) copy number was associated with higher GFR,
while haplotype-3 (GACGATAC) predicted lower GFR
(Chen et al. 2009).
In subjects from the NIDDK AASK (African-American
Study of Kidney Disease and Hypertension) trial, the
chronic decline rate of GFR was inﬂuenced by genetic
variation at CHGA, with the most prominent effect
(P = 0.006) from haplotype-1 in the 30-haplotype block,
spanning 30-UTR C ? 87T/rs7610 (Chen et al. 2009). The
effect was also seen for diploid haplotype pairs in that
block (P = 0.007).
We ﬁrst noted association of CHGA genetic variation
with circulating endothelin-1 (EDN1) (Lillie et al. 2007),
and then found that CHGA genetic variation or secretion
predicted not only EDN1 but also renal traits in a large
series of twin and sibling pairs (Chen et al. 2009). Plasma
CHGA positively correlated with EDN1 and negatively
correlated with GFR. Thus we explored the possible
mechanisms of CHGA effects on GFR as well as pro-
gression of kidney disease in culture cells. CHGA released
EDN1 from HUVEC (human umbilical vein endothelial
cells), dependent upon extracellular Ca
2? inﬂux through
voltage-operated Ca
2? channels, and inhibited by the 5-HT
(serotonin) antagonist cyproheptadine. The response was
also triggered by the CHGA synthetic amino terminus
(CHGA1-40). CHGA triggered endothelial co-release of
not only EDN1, but also von Willebrand Factor (vWF), and
angiopoietin-2, consistent with a global Weibel Palade
Body (i.e., endothelial secretory granule) exocytosis
response to CHGA. In renal glomerular cells, CHGA
caused secretion of EDN1 from glomerular endothelial
cells, and induced secretion of TGF-beta-1 from mesangial
cells co-cultured with glomerular endothelial cells, along
with TGF-beta-1 signal transduction (Chen et al. 2009).
In this series of studies of CHGA genetic variation on
disease, especially hypertension and hypertensive nephro-
sclerosis, we took advantage of multiple resources and
approaches, including intermediate phenotypes (biochem-
ical and/or physiological traits proceeding disease pheno-
types), different populations with replication, as well as
functional experiments in cella, to identify the pathways
whereby CHGA inﬂuences disease risk. Many of these
observations are consistent with the ‘‘common disease/
common allele’’ hypothesis for frequent traits in the pop-
ulation, and suggest new molecular strategies for probing
the pathophysiology, risk, and rational treatment of
hypertension and hypertensive nephrosclerosis. Other
observations, such as those on the unusual (minor allele
frequency *6%) CHGA coding variant Gly364Ser, in the
catecholamine release-inhibitory ‘‘catestatin’’ region of the
protein, indicate a role for rare variants in prediction of
cardiovascular risk (Rao et al. 2007).
‘‘Intermediate’’ Phenotypes
In the setting of late penetrance of the ultimate disease trait
(such as hypertension), as well as likely genetic heteroge-
neity, the ‘‘intermediate’’ phenotype (Lillie and O’Connor
2006; Shih and O’Connor 2008) strategy may be a useful
approach in the search for disease predisposition loci.
Autonomic traits with heritable determination may be of
particular value in investigation of the genetic underpin-
nings of hypertension. In accordance with this pathway
concept, we pursued intermediate traits in these studies.
Secretion of CHGA, estimated by its plasma concentration,
as well as the hemodynamic response to environmental
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123stressors (such as cold), may be predictors of the devel-
opment of later cardiovascular events, such as hypertension
(Markovitz et al. 1998; Menkes et al. 1989; Schneider et al.
2003; Snieder et al. 2002; Treiber et al. 2003). Such
responses, occurring even prior to the onset of disease,
would be useful biochemical or physiological ‘‘intermedi-
ate’’ phenotypes in probing the genetic determinants of
hypertension (Lillie and O’Connor 2006; O’Connor et al.
2000, 2002). When we analyzed the cold stress response in
our twin subjects, we found that that both change in BP and
ﬁnal (post-stress) BP are heritable, and thus may constitute
valuable intermediate phenotypic anchor points for hyper-
tension (Chen et al. 2008a, b).
Molecular Heterosis
The CHGA common promoter haplotype homozygosity
(CGATA/CGATA) and individual SNP G-462A effects
were more extreme for heterozygotes, suggesting ‘‘molec-
ular heterosis’’. The phenomenon of molecular heterosis has
been deﬁned as occurring when polymorphism at a single
genetic locus displays a signiﬁcantly greater or lesser effect
on a quantitative trait than homozygosity at the same locus.
Whilethephenomenonmayinitiallyseemcounter-intuitive,
it may be explained by one of several underlying mecha-
nisms, including a U-shaped dose–response relationship for
gene-on-trait, greater ‘‘ﬁtness’’ in heterozygotes, or hidden
stratiﬁcation in one homozygote class. One such stratiﬁca-
tion might be the effect of allelic variation at other (non-
CHGA)trans-QTLsoncoldstressandbasalBPs,suchasthe
associations we have reported for polymorphisms at tyro-
sine hydroxylase (TH) (Zhang et al. 2010a, b; Rao et al.
2007) or Rho kinase (ROCK2) (Seasholtz et al. 2006).
Sex: Role in Hypertension and Intermediate Phenotypes
In the wake of the sex-dependent effect of CHGA genetic
variation on BP, we question potential interactions of gene
and sex, and for CHGA we found that sex played a role at
each of several steps: biochemical, physiological, and
disease levels. Why adrenergic genetic variations yield
such different consequences in men and women? Acute
vascular responses to adrenergic stimuli are sex-dependent,
and the long-term consequences of repeated stressors on
resting blood pressure or the late appearance hypertension
differ by sex (Markovitz et al. 1998).
More recently, we established that common promoter
variation at two adrenergic loci, CHGB and TH (Zhang
et al. 2010a, b), disrupted DNA sequence matches for the
transcription factor SRY (Sex-determining Region Y), a
Y-chromosome-encoded HMG (high mobility group)-box
factor that may be instrumental in generating the male
phenotype, but which also has effects on gene expression in
the adult organism.
Chromogranin A and the Kidney: Potential Clinical
Implications
Since CHGA is important in storage and release of cate-
cholamines (Mahapatraetal. 2005;Vaingankar et al.2010a,
b), and is associated with hypertension (Chen et al. 2009,
2008a), it was reasonable to explore whether CHGA might
have an effect on hypertensive nephrosclerosis, via cate-
cholamines or hypertension. In our initial study of pre-
dominantly healthy twin pairs (Lillie et al. 2007), we found
that CHGA common genetic variation, especially in the
promoter region, predicted circulating EDN1 concentration.
We then found that CHGA polymorphism predicted the
occurrence of hypertensive renal disease in African-
Americans with the peak risk conferred by variation in the
30-region of the gene (Salem et al. 2008).
We ﬁnally proceeded to more mechanistic studies (Chen
et al. 2009), attempting to understand the links between
CHGA genetic variation, EDN1, and renal function. Here
CHGA displayed effects on GFR in healthy individuals, as
well as GFR decline rate in subjects with progressive of
renal disease, and the effects seemed independent of blood
pressure. EDN1 suggested a candidate pathway for explo-
ration: we then identiﬁed CHGA-induced release of other
endothelial mediators that could inﬂuence renal function,
including the vasoconstrictor and pro-ﬁbrotic EDN1, but
also the pro-coagulant vWF and the pro-angiogenic angio-
poietin-2. Co-release of all the three by CHGA from endo-
thelial cells was consistent with a mechanism whereby
CHGA triggered exocytosis of the endothelial cell secretory
granule: the Weibel Palade Body.
Why did a promoter block of CHGA best predict GFR in
healthy individuals, while a 30 block best predicted GFR
decline in subjects with renal dysfunction (Chen et al.
2009)? Transfected luciferase reporter studies of genetic
variants in these CHGA domains have now established that
variants in both the proximal promoter (Chen et al. 2008a)
and the 30-UTR (Chen et al. 2008b) are functional, and thus
capable of inﬂuencing disease traits. In our previous case/
control studies of hypertensive renal disease, 30-UTR vari-
ation was associated with ESRD (Salem et al. 2008), while
promoter variation resulting in alterations of nuclear hor-
mone receptor trans-activation may inﬂuence blood pres-
sure (Chen et al. 2008a).
Conclusion and Perspectives
Thus, common genetic variation across the human CHGA
locus is associated with cardio-renal disease traits as well
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123as their precursor (or ‘‘intermediate’’) phenotypes. The
associated variants are functional when tested in cellular
systems. Such ﬁndings may lead to novel approaches to the
pathophysiology, diagnosis, and treatment of the auto-
nomic dysfunction predisposing to such disease traits.
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